Oppenheimer Asset Management Inc. Has $5.88 Million Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Oppenheimer Asset Management Inc. raised its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 9.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 261,918 shares of the company's stock after purchasing an additional 21,590 shares during the period. Oppenheimer Asset Management Inc. owned about 0.22% of Privia Health Group worth $5,880,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. First Horizon Advisors Inc. increased its holdings in shares of Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after acquiring an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Privia Health Group by 7,833.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after acquiring an additional 2,350 shares during the last quarter. GAMMA Investing LLC grew its stake in Privia Health Group by 113.1% during the 1st quarter. GAMMA Investing LLC now owns 2,866 shares of the company's stock worth $64,000 after buying an additional 1,521 shares during the last quarter. Financial Management Professionals Inc. grew its stake in Privia Health Group by 28.7% during the 1st quarter. Financial Management Professionals Inc. now owns 3,383 shares of the company's stock worth $76,000 after buying an additional 754 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in Privia Health Group by 11.8% during the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after buying an additional 511 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Barclays upped their price objective on Privia Health Group from $23.00 to $24.00 and gave the stock an "equal weight" rating in a research note on Tuesday, May 27th. Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a research note on Thursday, April 10th. JPMorgan Chase & Co. increased their price target on Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 28th. JMP Securities reissued a "market outperform" rating and issued a $29.00 price target on shares of Privia Health Group in a research note on Monday, April 28th. Finally, Robert W. Baird upped their price objective on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a report on Tuesday, April 15th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Privia Health Group presently has an average rating of "Buy" and an average price target of $27.77.

Insider Activity

In related news, Director Matthew Shawn Morris sold 10,309 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $240,508.97. Following the transaction, the director now directly owns 59,792 shares of the company's stock, valued at approximately $1,394,947.36. The trade was a 14.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Mountcastle sold 5,630 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total value of $125,999.40. Following the transaction, the chief financial officer now directly owns 179,676 shares in the company, valued at $4,021,148.88. The trade was a 3.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,579 shares of company stock valued at $1,226,367 over the last three months. Insiders own 10.70% of the company's stock.

Privia Health Group Price Performance

Shares of NASDAQ PRVA remained flat at $22.00 during mid-day trading on Friday. The stock had a trading volume of 2,710,174 shares, compared to its average volume of 753,931. Privia Health Group, Inc. has a twelve month low of $16.47 and a twelve month high of $26.09. The firm has a market cap of $2.68 billion, a PE ratio of 183.35, a price-to-earnings-growth ratio of 3.52 and a beta of 0.83. The business's 50-day moving average is $23.16 and its 200 day moving average is $22.86.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.